Potential Treatment for Progressive MS Fails to Meet Endpoints
MedDay Pharmaceuticals announced that the second Phase III trial of its investigational product MD1003 did not meet its primary and secondary endpoints. The trial was designed to confirm the results of the first positive Phase III study in progressive multiple sclerosis (MS).
“We are very disappointed to learn of these results and hope that learnings from these trials can inform future efforts. This also underscores the vital importance of continued research in accelerating new treatments for people with progressive MS,” stated Professor Alan Thompson, Chair of the Scientific Steering Committee of the International Progressive MS Alliance
Detailed results of the SPI2 trial will be presented to the medical community at the upcoming American Academy of Neurology (AAN) 2020 Annual Meeting on April 29th in Toronto, Canada.
“We will review the findings in detail to understand these outcomes to help inform future clinical research in progressive MS and other neurological diseases,” commented Frédéric Sedel, MD, PhD, Chief Scientific Officer and co-Founder of MedDay Pharmaceuticals. “I remain confident of the importance of the neurometabolic approach to neurodegenerative diseases with high unmet medical need.”
Sign up to our e-newsletterfor updates from our growing global initiative to end progressive MS
Clicking submit confirms that you consent to MSIF sending you the Progressive MS Alliance newsletter
Please note, you must be aged 18 or older to subscribe to our newsletters.